NASDAQ OMX

LivaNova PLC Receives Regulatory Approval in Japan for the Solo Smart Stentless Tissue Aortic Valve

29.2.2016 15:00 | NASDAQ OMX

Del

LONDON, 2016-02-29 15:00 CET (GLOBE NEWSWIRE) --

LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN), a global medical technology company and a leader in the treatment of cardiovascular diseases, today announced that it has received approval from Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for its Solo Smart stentless tissue valve, the only valve designed to provide superior hemodynamics with the ease of a stented bioprosthesis implantation. 

Designed from bovine pericardium, the Solo Smart valve is fully biological with no synthetic material added, allowing the valve to mimic the healthy native aortic valve. Solo Smart maximizes the blood flow and delivers excellent hemodynamic performance and patient outcomes while providing a simplified implant procedure method with a removable stent for straightforward implantation and optimal positioning. 

“Since their introduction in the 1990s, stentless bioprosthetic valves have represented a major stride in valve design and hemodynamic performance for aortic valve replacement options,” said Alberto Repossini, M.D., Cardiac Surgery University of Brescia, Spedali Civili, Brescia, Italy. ”Solo Smart is a unique prosthesis with a temporary stent removed during its implantation for optimal positioning.  Once the stent is removed, Solo Smart becomes an entirely stentless valve, providing low pressure gradients and large orifice areas.”1,2,3,4,5,6

Available also in Europe and the U.S., the Solo Smart stentless valve is designed for patients with an active lifestyle, those who are at risk of PPM (Patient Prosthesis Mismatch) or require a concomitant aortic valve replacement procedure.

“In collaboration with our established partner, Japan Lifeline, LivaNova is pleased to introduce the Solo Smart stentless valve for aortic valve replacement in Japan,” said Michel Darnaud, President, Cardiac Surgery Business Unit, LivaNova.  “With Solo Smart valve and its long-term data paired with simplified implantability, surgeons are empowered with state-of-the-art technology and the confidence to perform AVR procedures more effectively.”

About LivaNova

LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems.  The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to LivaNova and assumptions that the parties believe to be reasonable.  LivaNova is not assuming any duty to update this information if those facts change or if the assumptions are no longer believed to be reasonable.  Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning developing novel opportunities in heart failure, sleep apnea and percutaneous mitral valve, creating new innovative solutions that benefit patients, healthcare professionals, and healthcare systems, and building significant shareholder value.  Important factors that may cause actual results to differ include, but are not limited to:  risks that the new businesses will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; the inability of LivaNova to meet expectations regarding the timing, completion and accounting and tax treatments; risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; unanticipated changes relating to competitive factors in the industries in which the company operates; the ability to hire and retain key personnel; the ability to attract new customers and retain existing customers in the manner anticipated; reliance on and integration of information technology systems; changes in legislation or governmental regulations affecting the company; international, national or local economic, social or political conditions that could adversely affect the company or its customers; conditions in the credit markets; risks to the industries in which LivaNova operates that are described in the "Risk Factors" section of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC by Cyberonics, Inc. and LivaNova and the analogous section in annual reports and other documents filed from time to time by Sorin S.p.A. with the Italian financial market regulator (CONSOB); risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; LivaNova’s' international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs.  The foregoing list of factors is not exhaustive.  You should carefully consider the foregoing factors and the other risks and uncertainties that affect the parties' businesses, including those described in Cyberonics' Annual Report on Form 10-K, as amended from time to time, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the SEC by Cyberonics and LivaNova and those described in Sorin's annual reports, registration documents and other documents filed from time to time with CONSOB by Sorin. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results.

________________________________

1 Repossini A, Rambaldini M, Lucchetti V, et al. Early clinical and hemodynamic results after aortic valve replacement with the Freedom SOLO bioprosthesis (experience of Italian multicenter study). Eur J Cardiothorac Surg. 2012;41(5):1104-111. 
2 Beholz S, Repossini A, Livi U, et al. The Freedom SOLO Valve for Aortic Valve Replacement: Clinical and Hemodynamic Results from a Prospective Multicenter Trial. The Journal of Heart Valve Disease. 2010;19:115-123. 
3 Horst M, Easo J, Hölzl PPF, et al. The Freedom Solo Valve: Mid-Term Clinical Results with a Stentless Pericardial Valve for Aortic Valve Replacement. The Journal of Heart Valve Disease. 2011;20:704-710.  
4 Clinical Experience With the Freedom Solo Stentless Aortic Valve in 277 Consecutive Patients. 
Thalmann M, Kaiblinger J, Krausler R, Pisarik H, Veit F, Taheri N, Kornigg K, Dinges C, Grabenwöger M, Stanger O. Ann Thorac Surg. 2014 Oct;98(4):1301-7. 
5 Clinical and haemodynamic outcomes in 804 patients receiving the Freedom SOLO stentless aortic valve: results from an international prospective multicentre study.  
Grubitzsch H, Wang S, Matschke K, Glauber M, Heimansohn D, Tan E, Francois K, Thalmann M.  
Eur J Cardiothorac Surg. 2015 Mar;47(3):e97-e104 
6 Long term durability and haemodynamic performance of freedom solo stentless valve for aortic valve replacement: a european, multicenter experience”. Repossini et al. Presented at AHA Congress – Nov 2015

         For more information, please visit www.livanova.com, or contact:
         
         Investor Relations:
         Vivid Sehgal
         Chief Financial Officer
         e-mail: investor.relations@livanova.com
         
         Investor Relations and Media:
         Greg Browne
         Senior Vice President, Finance
         Phone: +1 (281) 228-7262
         Fax: +1 (281) 218-9332
         e-mail: corporate.communications@livanova.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine23.8.2017 13:00Pressemelding

Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug.  23, 2017  (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is developing NanoFlu to protect older adults from seasonal influenza. The manuscript describes the formulation of Novavax' novel seasonal influenza vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization (WHO) recommended influenza strains. The study, conducted in ferrets, found that NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN) antibodies against a broad range of influenza subtypes. In a head-to-head comparison against standard-dose and high-do

Crown Bioscience Names Dr. Leon Hall Vice President of Global Scientific Excellence23.8.2017 12:29Pressemelding

SANTA CLARA, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience's scientific excellence initiatives. "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global

Blackbird Energy Inc. annonserer utnevnelsen av Allan Dixon som sjef for bedriftsutvikling23.8.2017 12:02Pressemelding

CALGARY, Alberta, 23. aug. 2017 (GLOBE NEWSWIRE) - Blackbird Energy Inc. (TSX-V:BBI) («Blackbird») har gleden av å kunngjøre utnevnelsen av Allan Dixon som sjef for bedriftsutvikling.  I denne rollen vil Dixon være ansvarlig for investorrelasjoner, kommunikasjonsinitiativer og strategiske bedriftsbevissthetsprogrammer i Nord-Amerika og Europa. Dixon har en omfattende bakgrunn i Calgarys olje- og gassindustri med erfaring fra investorrelasjoner ved Birchcliff Energy Ltd., aksjeanalyse ved National Bank Financial og investeringsrelatert bankvirksomhet ved Tristone Capital. Dixon har en bachelorgrad i handelsfag med spesialisering innen finans fra Dalhousie University. «Jeg er veldig glad for å ønske Allan velkommen til Blackbird-teamet, og jeg ser frem til å jobbe med ham. Med sin varierte bakgrunn og erfaring med å jobbe med noen av verdens fremste innovatører i bransjen, har jeg den største tillit til at han vil være et verdifullt tilskudd til teamet vårt og en ressurs fo

International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar23.8.2017 12:00Pressemelding

Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following. A photo is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10d6e5d8-c740-4c41-aa56-2255e6f70ad9 "Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for m

Nasdaq Offers Proprietary U.S. Equity Data Feeds from Equinix Data Center in London23.8.2017 09:11Pressemelding

NEW YORK and LONDON, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) has announced the availability of proprietary U.S. equity feeds from Equinix's London International Business Exchange(TM) (IBX®) data center - LD4 - located in Slough, U.K. As part of Nasdaq's efforts to bring U.S proprietary equities data to a larger audience, Nasdaq now offers Nasdaq TotalView and Nasdaq Basic from LD4. Nasdaq Basic combines Nasdaq Best Bid and Offer (QBBO), with either Nasdaq Last Sale (NLS), or Nasdaq Last Sale Plus (NLS Plus). "We continue to focus on working closely with our clients around the world in order to help them gain secure, efficient access to our markets," said Jeff Kimsey, Head of Global Data Products, Nasdaq. "Buy-and sell-side clients based in the U.K. can now access our U.S. data products directly from the exchange through the Equinix LD4 data center." This new Point of Presence (PoP) will allow firms direct access to U.S. mar

Real People Investment Holdings Limited: Nordic bondholders approved an extension of the standstill period in written procedure22.8.2017 20:47Pressemelding

Real People Investment Holdings Limited (the "Company") today announces the successful completion of a written procedure in relation to the Company's outstanding SEK 260,000,000 and NOK 135,000,000 senior unsecured callable bonds with ISINs SE0005392560 and NO0010689342 2013/2018. The Nordic bondholders  authorized the bondholders' agent to (i) consent to an extension of the last date of the Standstill Period (as defined in the Standstill Agreement referred to below) from no later than 31 August 2017 until no later than 30 November 2017, and (ii) approve that an addendum is made to the Standstill Agreement to the effect that the automatic termination of the Standstill Period upon certain events is qualified by the requirement that the Majority Standstill Creditors (as defined in the Standstill Agreement) also elects to terminate the Standstill Period (the "Proposal"). As previously communicated in press releases, the Real People Group is experiencing f

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom